EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection

Dimitri M Drekonja, Aasma Shaukat, Yuan Huang, Jane H Zhang, Andrew R Reinink, Sean Nugent, Jason A Dominitz, Anne Davis-Karim, Dale N Gerding, Tassos C Kyriakides

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae467 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Dimitri M Drekonja und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Minneapolis Veterans Affairs Health Care System, Minnesota, USA. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Clostridium Infections. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Cooperative Studies Program of the VA Office of Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clostridioides difficile infection (CDI) is the most common cause of healthcare–associated infections in US hospitals, with 15%–30% of patients experiencing recurrence. The aim of our randomized, double-blind clinical trial was to assess the efficacy of capsule-delivered fecal microbiota transplant (FMT) versus placebo in reducing recurrent diarrhea and CDI recurrence. The secondary aim was FMT safety assessment.

Methods

Between 2018 and 2022, Veterans across the Veterans Health Administration system with recurrent CDI who responded to antibiotic treatment were randomized in a 1:1 ratio to oral FMT or placebo capsules. Randomization was stratified by number of prior CDI recurrences (1 or ≥2). The primary endpoint was clinical recurrence by day 56, defined as >3 unformed stools daily for ≥2 days with or without laboratory confirmation of C. difficile, or death within 56 days.

Results

The study was stopped due to futility after meeting prespecified criteria. Of 153 participants (76 FMT, 77 placebo) with an average age of 66.5 years, 25 participants (32.9%) in the FMT arm and 23 (29.9%) in the placebo arm experienced the primary endpoint of diarrhea and possible or definite CDI recurrence or death within 56 days of capsule administration (absolute difference, 3.0% [95% confidence interval, −11.7% to 17.7%]). Stratification by number of recurrences revealed no statistically significant differences. There were no clinically important differences in adverse events.

Conclusions

FMT therapy versus placebo did not reduce CDI recurrence or death at 56 days. There were no meaningful differences in adverse events between treatment groups. Clinical Trials Registration NCT03005379.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationClostridium InfectionsHumansMaleFemaleDouble-Blind MethodAgedMiddle AgedClostridioides difficileRecurrenceDiarrheaTreatment OutcomeSecondary PreventionFeces

Stichwörter der Autor:innen

Clostridioides difficilediarrheafecal microbiota transplantationplacebosrandomized controlled trial

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Minneapolis Veterans Affairs Health Care System, Minnesota, USA.
  • Division of Gastroenterology, Department of Medicine, New York Harbor Veterans Affairs Healthcare System, New York, USA.
  • Veterans Affair Cooperative Studies Program Coordinating Center-West Haven, West Haven, Connecticut, USA.
  • Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
  • Division of Gastroenterology, Department of Medicine, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.
  • Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico, USA.

Förderung

  • Cooperative Studies Program of the VA Office of Research and Development

Zitieren

APA

Drekonja, D. M., Shaukat, A., Huang, Y., Zhang, J. H., Reinink, A. R., Nugent, S., Dominitz, J. A., Davis-Karim, A., Gerding, D. N., & Kyriakides, T. C. (2025). A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae467

Vancouver

Drekonja DM, Shaukat A, Huang Y, Zhang JH, Reinink AR, Nugent S, et al. A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae467

BibTeX
@article{Drekonja2025,
  author = {Drekonja, Dimitri M and Shaukat, Aasma and Huang, Yuan and Zhang, Jane H and Reinink, Andrew R and Nugent, Sean and Dominitz, Jason A and Davis-Karim, Anne and Gerding, Dale N and Kyriakides, Tassos C},
  title = {A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae467}
}
Kostenlos starten →